There has been significant progress in so-called bioprinting – using a type of 3D printing to manufacture biological tissues. But an actual organ had not been accomplished – until now.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.
This yearly review analyzes recent developments, trends and outlooks in the areas of biotechnology, biosimilars, biopharmaceuticals, biologics, biomarkers and biobanks.
Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.
Results from NASA’s landmark Twins Study reveals some interesting, surprising and reassuring data.
Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.
Researchers with the Icahn School of Medicine at Mount Sinai in New York have had promising results with a cancer vaccine.
Taking caffeine before exercise could improve performance during a broad range of exercise tasks, according to a new review of past research.
A new report published by researchers at Northwestern University offers the possibility of an early diagnostic test for Alzheimer’s disease – via an eye test.
Blood pressure and stroke risk rise steadily the more alcohol people drink, and previous claims that one or two drinks a day might protect against stroke are not true, according to a genetic study.
Scientists at the National Institutes of Health (NIH) launched a trial to examine a potential universal flu vaccine candidate, known as H1ssF_3928.
ViiV Healthcare presented three-year data from the SWORD 1 and 2 clinical trials in HIV.